FIELD: pharmacology.
SUBSTANCE: invention relates to a new pyridopyrimidine compound of general formula (Ia), a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compounds have AKT-mTOR (PI3K-AKT-mTOR) phosphatidylinositol-3-kinase kinase inhibitor properties and can be used to treat a disease or condition caused by dysfunction of the PI3K-AKT-mTOR signaling pathway, in particular a tumour disease. In the general formula 
(Ia), where each of R1 and R2 independently is 3-oxa-8-azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl or NRARB, and at least one of R1 and R2 is 3-oxa-8-azabicyclo[3.2.1]octanyl or 8-oxa-3-azabicyclo[3.2.1]octanyl; and each of the RA and RB independently represents C1-C6alkyl, unsubstituted or substituted C1-C6alkoxy, or RA and RB together with N to which they are attached, form a morpholino ring which is unsubstituted or substituted C1-C6 alkyl; and R3 is 
, where Rc is C1-C3 alkyl.
EFFECT: increased efficiency of compounds application.
9 cl, 2 tbl, 52 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ISOXAZOLIL ETHER DERIVATIVES AS PAM GABA A ALFA5 | 2019 |
|
RU2800160C2 |
| MORPHOLINO-SUBSTITUTED DERIVATIVES OF BICYCLIC PYRIMIDINE UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2609208C2 |
| DIFLUOROMETHYLAMINOPYRIDINES AND DIFLUOROMETHYLAMINOPYRIMIDINES | 2015 |
|
RU2712091C2 |
| TREATMENT OF NEUROLOGICAL DISORDERS | 2017 |
|
RU2765868C2 |
| 3,3-DISUBSTITUTED-(8-AZABICYCLO[3.2.1]OCTA-8-YL)-[5-(1H-PYRASOL-4-YL)-THIOPHEN-3-YL]- METHANONE AND RELATED COMPOUNDS AND THEIR USE | 2011 |
|
RU2593753C2 |
| PYRROLIDINE AND PIPERIDINE COMPOUNDS | 2020 |
|
RU2803455C1 |
| NEW BIPHENYL COMPOUND OR ITS SALT | 2018 |
|
RU2765152C2 |
| 1-(3-AMINOPROPYL)-SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 2014 |
|
RU2671179C2 |
| ANTITUMOR EFFECT ENHANCER USING NEW BIPHENYL COMPOUND | 2018 |
|
RU2765153C2 |
| 1,2,4-TRIAZOLONE DERIVATIVE | 2011 |
|
RU2566754C2 |
